Drastic Reduction of Piperacillin-Tazobactam Concentrations in an in-vitro Model of Continuous Venovenous Hemofiltration: Proposal of An Innovative Modality of Administration to Maintain them at Constant Concentration

ISSN: 1875-6182 (Online)
ISSN: 1871-5257 (Print)


Volume 12, 3 Issues, 2014


Download PDF Flyer




Cardiovascular & Hematological Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Cardiovascular & Hematological Agents

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Debabrata Mukherjee
Department of Internal Medicine Texas Tech University
4800 Alberta Avenue El Paso
Texas, 79905
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Drastic Reduction of Piperacillin-Tazobactam Concentrations in an in-vitro Model of Continuous Venovenous Hemofiltration: Proposal of An Innovative Modality of Administration to Maintain them at Constant Concentration

Author(s): Michele Ferrannini, Pasquale Niscola, Clorinda Falcone, Annalisa Noce, Anna Pastore, Gianna Di Giovamberardino, Andrea Tendas, Laura Scaramucci, Nicola Di Daniele and Roberto Palumbo

Affiliation: Piazzale dell’Umanesimo, 10, 00144 – Roma, Italy.

Abstract

Background/Aims: Critically-ill patients often undergo continuous renal replacement therapy (CRRT) and need antimicrobial therapy. Piperacillin and tazobactam (Pip-Tzb) are cleared by CRRT. Our aim is to evaluate Pip-Tzb removal in an in-vitro-single-pool-model of continuous-veno-venous-hemofiltration (CVVH); we test a new method of Pip-Tzb administration during CRRT assuring constant levels of concentrations above the minimum inhibitory concentration (MIC).

Methods: In an in-vitro-single-pool-model of CVVH, two solutions (Protein-Free-Solution, PFS and Fresh-Frozen- Plasma, FFP) added with Pip-Tzb were tested for Pip-Tzb removal and adsorption. Then, to keep concentrations constantly above the MIC during CVVH, we add Pip-Tzb in the reinfusion bags.

Results: Pip-Tzb rapidly decreased than the MIC during CVVH. The adsorption was irrelevant in the test with FPS. Adding Pip-Tzb in the reinfusion bags of the CVVH system, we observed constant concentrations of Pip-Tzb over time.

Conclusion: The association of Pip-Tzb is rapidly cleared with a real risk of inadequate dosages in patients undergoing CRRT. Adding Pip-Tzb in the reinfusion bags above the MIC, we obtained stability of concentrations during CVVH.


Keywords: Antibiotic, antimicrobial therapy, continuous renal replacement therapy, continuous venovenous hemofiltration, drug clearance, dyalisis, in vitro investigation, infection, minimum inhibitory concentration (MIC), piperacillin, sepsis, tazobactam.

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 11
Issue Number: 3
First Page: 187
Last Page: 193
Page Count: 7
DOI: 10.2174/187152571103140120102359
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science